INTERWEST VENTURE MANAGEMENT CO - Q2 2020 holdings

$121 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 11 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 8.3% .

 Value Shares↓ Weighting
REAL  THE REALREAL$65,921,000
+82.5%
5,154,0800.0%54.67%
+43.2%
GKOS SellGLAUKOS CORP$24,833,000
-20.6%
646,364
-36.2%
20.59%
-37.7%
AGTC  APPLIED GENETIC TECHNOL CORP$8,066,000
+68.9%
1,455,9040.0%6.69%
+32.6%
EIGR  EIGER BIOPHARMACEUTICALS INC$7,343,000
+41.2%
764,9180.0%6.09%
+10.8%
CDTX  CIDARA THERAPEUTICS INC$5,007,000
+48.8%
1,356,8130.0%4.15%
+16.8%
KALV  KALVISTA PHARMACEUTICALS INC$4,704,000
+58.2%
388,7660.0%3.90%
+24.2%
VERO  VENUS CONCEPT INC$2,299,000
-1.7%
658,6570.0%1.91%
-22.8%
STIM  NEURONETICS INC$1,989,000
+2.1%
1,030,6890.0%1.65%
-19.9%
 OBALON THERAPEUTICS INC$268,000
-2.2%
380,2240.0%0.22%
-23.2%
XENE  XENON PHARMACEUTICALS INC$104,000
+10.6%
8,2930.0%0.09%
-13.1%
DARE  DARE BIOSCIENCE INC$50,000
+16.3%
50,3680.0%0.04%
-8.9%
MGNX ExitMACROGENICS INC$0-1,074,316
-100.0%
-6.60%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-07-23
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
GLAUKOS CORP28Q3 202333.0%
EIGER BIOPHARMACEUTICALS INC24Q3 202217.7%
APPLIED GENETIC TECHNOL CORP24Q3 20226.7%
XENON PHARMACEUTICALS INC20Q3 20210.6%
CIDARA THERAPEUTICS INC19Q2 20214.5%
THE REALREAL18Q3 202362.6%
KALVISTA PHARMACEUTICALS INC17Q4 202010.8%
DARE BIOSCIENCE INC16Q3 20230.3%
MACROGENICS INC14Q1 202019.2%
PMV PHARMACEUTICALS INC13Q3 202367.5%

View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.

Latest filings
TypeFiled
1442024-02-27
13F-HR2023-10-20
13F-HR2023-07-21
13F-HR2023-04-27
13F-HR2023-01-31
13F-HR2022-10-25
13F-HR2022-08-02
13F-HR2022-04-13
13F-HR2022-01-25
13F-HR2021-10-19

View INTERWEST VENTURE MANAGEMENT CO's complete filings history.

Compare quarters

Export INTERWEST VENTURE MANAGEMENT CO's holdings